In March 2026, Weiyuan Synthetic Biology proudly announced the successful closure of its Series A+ funding round, securing a substantial 300 million yuan. This round was co-led by Huirong Fund, a subsidiary of Henan Investment Group, and Tan Ruiqing. The newly acquired funds will be strategically allocated to broaden the horizons of AI biocomputing applications, intensify research and development efforts in core technologies, and facilitate the implementation of these technologies across various scenarios. Notably, Henan Investment Group had already cemented its position in the AI infrastructure landscape, with investments spanning chip development, ultra-large-scale computing power infrastructure, and HALO asset integration, thereby offering robust computing support for AI-driven applications. In a parallel move, Weiyuan Synthetic Biology, in partnership with esteemed institutions such as Stanford University and Peking University, unveiled the open collaboration platform PoseX at ICLR 2026. By curating a vast, real-world-focused open-source docking evaluation dataset, this initiative tackles the challenge of limited benchmark data for assessing molecular docking algorithms, thereby propelling digital innovation in the realms of biomanufacturing and industrial enzyme design.